Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · Real-Time Price · USD
11.84
+0.26 (2.25%)
At close: Oct 20, 2026, 4:00 PM EDT
11.92
+0.08 (0.68%)
After-hours: Oct 20, 2026, 7:57 PM EDT
Intellia Therapeutics Employees
Intellia Therapeutics had 377 employees as of December 31, 2025. The number of employees decreased by 26 or -6.45% compared to the previous year. That makes Intellia Therapeutics the 22,232nd largest employer in the world and 2,893rd in the United States.
Employees
377
Change (1Y)
-26
Growth (1Y)
-6.45%
Revenue / Employee
$157,841
Profits / Employee
-$1,060,942
Market Cap
1.66B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 377 | -26 | -6.45% |
| Dec 31, 2024 | 403 | -123 | -23.38% |
| Dec 31, 2023 | 526 | -72 | -12.04% |
| Dec 31, 2022 | 598 | 113 | 23.30% |
| Dec 31, 2021 | 485 | 173 | 55.45% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Immunocore Holdings | 524 |
| Vir Biotechnology | 367 |
| Nuvation Bio | 305 |
| UroGen Pharma | 300 |
| Biohaven | 274 |
| Stoke Therapeutics | 170 |
| Zenas BioPharma | 167 |
| Maze Therapeutics | 141 |
NTLA News
- 7 days ago - Intellia Therapeutics appoints Jing Marantz as chief medical officer - TheFly
- 7 days ago - Intellia Therapeutics Appoints Jing L. Marantz, M.D. - GlobeNewsWire
- 14 days ago - Barclays starts Intellia at Underweight on expected commercial headwinds - TheFly
- 14 days ago - Intellia Therapeutics initiated with an Underweight at Barclays - TheFly
- 15 days ago - Cathie Wood’s ARK Investment buys 96K shares of Intellia Therapeutics today - TheFly
- 18 days ago - Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 19 days ago - Cathie Wood’s ARK Investment buys 411K shares of Intellia Therapeutics today - TheFly
- 20 days ago - Cathie Wood’s ARK Investment buys 467K shares of Intellia Therapeutics today - TheFly